Tang Capital Management’s CytomX Therapeutics CTMX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $25.1M | Buy |
11,065,662
+4,347,837
| +65% | +$9.87M | 1.27% | 23 |
|
|
2025
Q1 | $4.27M | Sell |
6,717,825
-593,935
| -8% | -$378K | 0.24% | 78 |
|
|
2024
Q4 | $7.53M | Sell |
7,311,760
-500,000
| -6% | -$515K | 0.5% | 56 |
|
|
2024
Q3 | $9.22M | Buy |
7,811,760
+19,824
| +0.3% | +$23.4K | 0.66% | 45 |
|
|
2024
Q2 | $9.51M | Buy |
7,791,936
+1,341,936
| +21% | +$1.64M | 0.97% | 34 |
|
|
2024
Q1 | $14.1M | Sell |
6,450,000
-100,000
| -2% | -$218K | 1.46% | 22 |
|
|
2023
Q4 | $10.2M | Buy |
6,550,000
+100,000
| +2% | +$155K | 0.94% | 29 |
|
|
2023
Q3 | $8.32M | Sell |
6,450,000
-150,000
| -2% | -$194K | 1.17% | 28 |
|
|
2023
Q2 | $11.4M | Buy |
6,600,000
+506,968
| +8% | +$872K | 1.67% | 19 |
|
|
2023
Q1 | $9.2M | Buy |
6,093,032
+2,582,587
| +74% | +$3.9M | 1.37% | 27 |
|
|
2022
Q4 | $5.62M | Buy |
3,510,445
+10,445
| +0.3% | +$16.7K | 0.82% | 32 |
|
|
2022
Q3 | $5.08M | Buy |
3,500,000
+2,445,327
| +232% | +$3.55M | 0.62% | 42 |
|
|
2022
Q2 | $1.93M | Buy |
+1,054,673
| New | +$1.93M | 0.29% | 51 |
|
|
2022
Q1 | – | Sell |
-152,345
| Closed | -$660K | – | 52 |
|
|
2021
Q4 | $660K | Buy |
+152,345
| New | +$660K | 0.13% | 29 |
|
|
2020
Q4 | – | Sell |
-112,880
| Closed | -$751K | – | 13 |
|
|
2020
Q3 | $751K | Sell |
112,880
-187,120
| -62% | -$1.24M | 0.14% | 19 |
|
|
2020
Q2 | $2.5M | Hold |
300,000
| – | – | 0.24% | 17 |
|
|
2020
Q1 | $2.3M | Buy |
+300,000
| New | +$2.3M | 0.32% | 19 |
|